A B-T Fassas

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi Tandem transplants in the treatment of multiple myeloma. Pro
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 2:303-4. 2004
  2. ncbi Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 118:1041-7. 2002
  3. ncbi Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 119:164-8. 2002
  4. ncbi Predicting long-term survival in multiple myeloma patients following autotransplants
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AK 72205, USA
    Leuk Lymphoma 44:749-58. 2003
  5. ncbi Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 123:484-9. 2003
  6. ncbi Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA
    Leuk Lymphoma 45:291-300. 2004
  7. ncbi Chromosome 13 deletion/hypodiploidy and prognosis in multiple myeloma patients
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock 72205, USA
    Leuk Lymphoma 45:1083-91. 2004
  8. ncbi Cure of myeloma: hype or reality?
    A Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 35:215-24. 2005
  9. ncbi Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation
    A B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Leuk Lymphoma 46:1159-61. 2005
  10. ncbi Separating graft-versus-tumor from graft-versus-host reactions
    A B T Fassas
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Leuk Lymphoma 43:725-33. 2002

Detail Information

Publications31

  1. ncbi Tandem transplants in the treatment of multiple myeloma. Pro
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 2:303-4. 2004
  2. ncbi Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 118:1041-7. 2002
    ..Furthermore, these parameters in combination with easily obtained pretransplant levels of beta-2 microglobulin and albumin define three groups of MM patients with clearly distinct outcomes...
  3. ncbi Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 119:164-8. 2002
    ..Other approaches may be required to improve survival in multiple myeloma...
  4. ncbi Predicting long-term survival in multiple myeloma patients following autotransplants
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AK 72205, USA
    Leuk Lymphoma 44:749-58. 2003
    ..Furthermore, patients with less favorable outcome should be identified early in their disease course and should be managed with novel and hopefully more effective treatments...
  5. ncbi Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 123:484-9. 2003
    ..In conclusion, a sizeable fraction of myeloma patients relapsing after tandem autotransplants without poor-risk features enjoyed meaningful survival prolongation when appropriately treated...
  6. ncbi Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA
    Leuk Lymphoma 45:291-300. 2004
    ..Application of allogeneic transplantation and administration of prophylactic CNS treatment are also discussed. Further elucidation of the factors predisposing patients with high-risk disease features to CNS myeloma involvement is needed...
  7. ncbi Chromosome 13 deletion/hypodiploidy and prognosis in multiple myeloma patients
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock 72205, USA
    Leuk Lymphoma 45:1083-91. 2004
    ..Based on this stratification, high-risk patients are excellent candidates for novel therapeutic approaches, such as planned non-myeloablative allogeneic transplants following an autologous transplant...
  8. ncbi Cure of myeloma: hype or reality?
    A Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 35:215-24. 2005
    ..Currently non-myeloablative, allogeneic transplants (and possibly proteasome inhibitors) are the most promising approaches for high-risk patients...
  9. ncbi Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation
    A B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Leuk Lymphoma 46:1159-61. 2005
    ..A cut-off point of 100 mg/l (CRP levels) and 15 mg/l/day (CRP velocity) identified patients likely to suffer severe complications with 86 and 75% sensitivity, respectively. Prospective validation of this model is currently underway...
  10. ncbi Separating graft-versus-tumor from graft-versus-host reactions
    A B T Fassas
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Leuk Lymphoma 43:725-33. 2002
    ....
  11. ncbi Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations
    Athanasios B T Fassas
    Myeloma and Transplantation Research Center, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 117:103-8. 2002
    ..Given this universally poor prognosis, the application of allogeneic transplants should be studied in this clinical setting...
  12. ncbi Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation
    A B Fassas
    Department of Internal Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, USA
    Leuk Lymphoma 42:1323-8. 2001
    ..The regimen was very well tolerated. Speculations about a possible mechanism of action of tamoxifen in multiple myeloma are discussed...
  13. ncbi Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma
    I Gojo
    Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Bone Marrow Transplant 37:65-72. 2006
    ..In order to improve results following autotransplantation, novel agents or immunologic approaches should be studied in the post-transplant setting...
  14. ncbi Transplantation as salvage therapy for high-risk patients with myeloma in relapse
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 30:873-8. 2002
    ..001). Their survival at 2 years post-ST was 43%, 17% and 11%, respectively. Our study suggests further transplantation should only be considered in the setting of a clinical trial in patients with favorable prognostic factors...
  15. ncbi Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:822-9. 2001
    ..MEL-140 had an acceptable toxicity and appeared equally effective as MEL-200. In the setting of renal failure, the role of auto-SCT early in the disease course and benefits of tandem SCT require further evaluation...
  16. ncbi Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy
    A Fassas
    Department of Medicine, Division of Bone Marrow and Stem Cell Transplantation, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
    Bone Marrow Transplant 28:399-403. 2001
    ..Although CDEP-induced pneumonitis appears to be a rare complication, its early recognition and prompt treatment, as well as its possible association with preceding fungal infection may have important clinical implications...
  17. ncbi Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:600-7. 2001
    ..In conclusion, MEL-140 is less toxic and appears equally as efficacious as MEL-200 in elderly patients. The benefits of tandem SCT in this patient population need further evaluation in a randomized trial...
  18. ncbi High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity
    I Gojo
    Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Bone Marrow Transplant 34:69-76. 2004
    ..Cyclophosphamide alone is associated with impressive CD34(+) cell yields and clear antimyeloma activity. The addition of etoposide resulted in increased toxicity without significant improvement in CD34(+) cell yield or response rates...
  19. ncbi Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model
    M L Grazziutti
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 38:501-6. 2006
    ..Pharmacogenomic and pharmacokinetic studies are needed to better understand interpatient variability of melphalan exposure and toxicity...
  20. ncbi Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma
    A Fassas
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Semin Hematol 38:231-42. 2001
    ..Special emphasis is placed on the safety and efficacy of transplant in elderly patients and in those with impaired renal function, who are usually excluded from the most effective therapy...
  21. ncbi High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
    A Badros
    Myeloma and Transplantation Research Center and Department of Pathology, University of Arkansas for Medical Sciences and Veterans Health System, Little Rock, USA
    Blood 97:2574-9. 2001
    ..Remarkable graft versus myeloma responses were seen in chemotherapy-refractory patients. Two patients died of progressive disease, and 3 died of GVHD complications without active disease. GVHD remains a major problem with this procedure...
  22. ncbi Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
    K R Desikan
    The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 112:242-7. 2001
    ..Patients with high tumour burden, i.e. beta(2)-microglobulin levels > 2.5 mg/l, probably benefit from chemotherapy for mobilization both in terms of cytoreduction and adequate stem cell mobilization resulting in accelerated engraftment...
  23. ncbi Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
    M Zangari
    Central Arkansas Veteran s Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Blood Coagul Fibrinolysis 13:187-92. 2002
    ..In conclusion, in this series, acquired APC resistance was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of DVT...
  24. ncbi Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Bone Marrow Transplant 33:823-8. 2004
    ..05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course...
  25. ncbi Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy
    A P Rapoport
    Greenebaum Cancer Center and Stem Cell Transplantation Program, University of Maryland School of Medicine, Baltimore, MD, USA
    Bone Marrow Transplant 29:303-12. 2002
    ..015). In conclusion, post-transplant consolidation therapy is feasible and well-tolerated for patients autografted for aggressive NHL and HD and may be associated with improved progression-free survival particularly for patients with HD...
  26. ncbi Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Bone Marrow Transplant 37:511-5. 2006
    ....
  27. ncbi Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients
    M L Grazziutti
    Myeloma Institute of Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 37:403-9. 2006
    ..We conclude that the IRF-D is a simple, inexpensive and widely available test that can predict marrow recovery several days before ANC> or = 100/microl...
  28. ncbi Thalidomide in the management of multiple myeloma
    B Barlogie
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Semin Hematol 38:250-9. 2001
    ..The virtual lack of myelosuppression makes it an ideal agent for combination with cytotoxic chemotherapy. Newer, more potent, and less toxic derivatives of thalidomide are being evaluated...
  29. ncbi Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients
    M H Miceli
    Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Bone Marrow Transplant 37:857-64. 2006
    ..Increased pre-transplant BMIS and smoking are significant predictors of severe infection after myeloablative chemotherapy followed by ASCT in myeloma patients...
  30. ncbi 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes
    T Mahfouz
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, 72205, USA
    J Clin Oncol 23:7857-63. 2005
    ..To determine the role of FDG-PET in the diagnosis of infection in patients with multiple myeloma (MM)...
  31. ncbi Multiple myeloma: clinical review and diagnostic imaging
    Edgardo J C Angtuaco
    Department of Radiology and the Myeloma Institute, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 596, Little Rock, AR 72205, USA
    Radiology 231:11-23. 2004
    ..These biopsies have resulted in increased identification of cytogenetic abnormalities, particularly the presence of chromosome 13 deletion, which is a grave prognostic indicator in MM...